Repro Med Sys Inc (REPR) 0.4247 $REPR
Repro Med Systems, Inc. (REPR) Announces Appointment of New CFO
ACCESSWIRE - Tue Jan 20, 6:04AM CST
CHESTER, NY / ACCESSWIRE / January 20, 2015 / Repro-Med Systems, Inc. dba RMS Medical Products (OTCQB:REPR) today announced the appointment of Karen Fisher who will serve as Chief Financial Officer of RMS effective January 28th, 2015.
NYT: 14.02 (+0.08)
Repro Med Systems, Inc. (Repr) Announces Strong Results for Third Quarter Ended November 30, 2014
ACCESSWIRE - Tue Dec 23, 11:14AM CST
CHESTER, NY / ACCESSWIRE / December 23, 2014 / Repro Med Systems, Inc. dba RMS Medical Products (OTC stock symbol REPR) today announced that its year-to-date net revenues for fiscal year 2015 are up 28.6% compared with last year, led by its line of home infusion products, while third quarter net revenues for fiscal 2015 increased 21.8% from fiscal 2014. The company's current fiscal year ends February 28, 2015.
RMS Medical Products Secures Additional Growth Capital
ACCESSWIRE - Mon Aug 11, 3:51PM CDT
Chester, NY / ACCESSWIRE / August 11, 2014 / Repro-Med Systems Inc., d/b/a RMS Medical Products (OTC stock symbol REPR) announced today that it secured growth capital commitments from the Horton Capital Partners Fund ("Horton Capital"
. Horton Capital, an institutional investor based in Philadelphia, PA, agreed to purchase 1 million shares at $0.288 per share (the closing price of the Shares on August 
and received warrants to purchase an additional 1 million shares should the share price appreciate to above $0.45 (a 56% premium). The proceeds will be used to fund future growth as the RMS team works to execute their plan and take advantage of significant opportunities being presented to the company in the infusion market. Andrew I. Sealfon, the company's President and Chief Executive Officer, said, "I am delighted to be working with Horton Capital. They have been shareholders for some time now and bring a network and level of experience which should be invaluable in the company's efforts to grow and enhance value for all of our shareholders."
RMS Announces Increased Sales, Organization and Personnel Changes
ACCESSWIRE - Thu Jun 12, 2:26PM CDT
Chester, NY / ACCESSWIRE / June 12, 2014 / Repro-Med Systems Inc., d/b/a RMS Medical Products (OTC stock symbol REPR) today announced a 41.1% increase in sales for the first quarter of fiscal year 2015 as compared with the first quarter of fiscal 2014. The company's fiscal year runs from March through February. Net sales totaled $2,647,000 during the first quarter of the current fiscal year, compared with $1,876,000 for the same period a year ago and exceeded the revenues from the previous quarter.
BSX: 18.07 (+0.22)
Repro Med Systems, Inc. (REPR) Announces Appointment of New CFO
ACCESSWIRE - Tue Jan 20, 6:04AM CST
CHESTER, NY / ACCESSWIRE / January 20, 2015 / Repro-Med Systems, Inc. dba RMS Medical Products (OTCQB:REPR) today announced the appointment of Karen Fisher who will serve as Chief Financial Officer of RMS effective January 28th, 2015.
NYT: 14.02 (+0.08)
Repro Med Systems, Inc. (Repr) Announces Strong Results for Third Quarter Ended November 30, 2014
ACCESSWIRE - Tue Dec 23, 11:14AM CST
CHESTER, NY / ACCESSWIRE / December 23, 2014 / Repro Med Systems, Inc. dba RMS Medical Products (OTC stock symbol REPR) today announced that its year-to-date net revenues for fiscal year 2015 are up 28.6% compared with last year, led by its line of home infusion products, while third quarter net revenues for fiscal 2015 increased 21.8% from fiscal 2014. The company's current fiscal year ends February 28, 2015.
RMS Medical Products Secures Additional Growth Capital
ACCESSWIRE - Mon Aug 11, 3:51PM CDT
Chester, NY / ACCESSWIRE / August 11, 2014 / Repro-Med Systems Inc., d/b/a RMS Medical Products (OTC stock symbol REPR) announced today that it secured growth capital commitments from the Horton Capital Partners Fund ("Horton Capital"
. Horton Capital, an institutional investor based in Philadelphia, PA, agreed to purchase 1 million shares at $0.288 per share (the closing price of the Shares on August and received warrants to purchase an additional 1 million shares should the share price appreciate to above $0.45 (a 56% premium). The proceeds will be used to fund future growth as the RMS team works to execute their plan and take advantage of significant opportunities being presented to the company in the infusion market. Andrew I. Sealfon, the company's President and Chief Executive Officer, said, "I am delighted to be working with Horton Capital. They have been shareholders for some time now and bring a network and level of experience which should be invaluable in the company's efforts to grow and enhance value for all of our shareholders." RMS Announces Increased Sales, Organization and Personnel Changes
ACCESSWIRE - Thu Jun 12, 2:26PM CDT
Chester, NY / ACCESSWIRE / June 12, 2014 / Repro-Med Systems Inc., d/b/a RMS Medical Products (OTC stock symbol REPR) today announced a 41.1% increase in sales for the first quarter of fiscal year 2015 as compared with the first quarter of fiscal 2014. The company's fiscal year runs from March through February. Net sales totaled $2,647,000 during the first quarter of the current fiscal year, compared with $1,876,000 for the same period a year ago and exceeded the revenues from the previous quarter.
BSX: 18.07 (+0.22)
